Recent Blog Posts

View Post: Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With ...
29 Oct 2009 by Wang, Oki, Pro, Romaguera, Rodriguez, Samaniego...  
150000/µL received a dose of 0.4 mCi/kg of 90Y–ibritumomab tiuxetan, whereas those with a platelet count less than 150000/µL received a dose of 0.3 mCi/kg. Results Thirty-four patients with a median age of 68 years (range, ...
View Blog: Journal of Clinical Oncology Current Issue - http://jco.ascopubs.org/

---

View Post: Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With ...
3 Nov 2009
PurposeThis phase II trial evaluated the safety and efficacy of yttrium-90 (90Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL). Patients and MethodsPatients with relapsed or refractory MCL were ...
View Blog: Pubget: Journal of Clinical Oncology[latest] - http://pubget.com/search?q=Journal+of+Clinical+Onc...

---

View Post: Production of an Isomeric State of ^{90}Y by Fast Neutrons for ...
9 Nov 2009 by Yasuki Nagai, Osamu Iwamoto, Nobuyuki Iwamoto,...  
90gY-ibritumomab tiuxetan is a radiopharmaceutical agent containing a radionuclide, 90gY, the ground state of 90Y. It has been extensively used for cancer therapy,1–3) in which. -rays from the decay of 90gY with a half-life of 2.7 d to ...
View Blog: Recent articles in J. Phys. Soc. Jpn. - http://www.ipap.jp/jpsj/

---

View Post: First report on a prospective trial with yttrium-90-labeled ...
6 Aug 2009 by Maza, S., Kiewe, P., Munz, DL, Korfel,...  
The aim of this phase II trial was to evaluate the therapeutic efficacy, toxicity, and biodistribution of yttrium-90 (90Y) ibritumomab tiuxetan in PCNSL. Ten patients with relapsed PCNSL were included in a phase II trial and treated ...
View Blog: Neuro-Oncology current issue - http://neuro-oncology.dukejournals.org/

---

View Post: Bayer's Bold New Bet Fails to Rain on Spectrum Pharmaceuticals ...
3 Sep 2009 by Michael Becker  
However, Zevalin® [ibritumomab tiuxetan] employs yttrium-90 as its therapeutic payload, while Bexxar® [tositumomab] uses iodine-131. Despite great promise and STaRT's established safety and efficacy, a July 14, 2007, article in the New ...
View Blog: MD Becker Partners LLC: Blog Site - http://mdbpartners.wordpress.com/

---

View Post: ibritumomab tiuxetan for follicular non-hodgkin's lymphoma
5 Sep 2009
zevalin (ibritumomab tiuxetan), a cd20-directed radiotherapeutic antibody, received approval from the us food and drug administration (fda) for an expanded label for the treatment of patients with previously untreated follicular ...
View Blog: Current R&D of Pharmaceutical - http://www.cradop.com/component/content/frontpage.html

---

View Post: The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with ...
14 Oct 2009 by Evens, A. M., Spies, W. G., Helenowski,...  
We subsequently completed a phase I clinical trial combining escalating doses of motexafin gadolinium concurrently with standard [90Y]ibritumomab tiuxetan for patients with relapsed/refractory non-Hodgkin's lymphoma. ...
View Blog: Clinical Cancer Research recent issues - http://clincancerres.aacrjournals.org/

---

View Post: Trading Outlook for Spectrum Pharmaceuticals Inc. (SPPI)
15 Oct 2009 by admin  
(CTI) partnered to form a joint venture RIT Oncology LLC (RIT) to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology LLC ...
View Blog: Beacon Equity Research - http://www.beaconequity.com/

---